Oncolytic viruses (OVs) are emerging as potentially useful platforms in treatment methods for
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …

Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first
OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor
of the central nervous system and has a very poor prognosis. The current standard of care …

Simple Summary Within this review article the authors provide an unbiased review of the
oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors …

Oncolytic viruses (OVs) can selectively kill tumor cells without affecting normal cells, as well
as activate the innate and adaptive immune systems in patients. Thus, they have been …

Tumors represent a hostile environment for the effector cells of cancer immunosurveillance.
Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly …

In cancer immunotherapy, a patient's own immune system is harnessed against cancer.
Immune checkpoint inhibitors release the brakes on tumor-reactive T cells and, therefore …

Oncolytic viruses (OVs) represent a highly promising treatment strategy for a wide range of
cancers, by mediating both the direct killing of tumor cells as well as mobilization of …

Oncolytic viruses (OVs) are an emerging class of therapeutics which combine multiple
mechanisms of action, including direct cancer cell-killing, immunotherapy and gene therapy …

Glioblastoma is the most common primary malignant brain tumor in adults and outcomes
remain poor despite the current standard of care multimodal therapy. Oncolytic virotherapy …